ArticleJournal of personalized medicine2020
Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 28 citations in OpenAlex.
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?Frontiers in oncology · 2026Article
- Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.JCO precision oncology · 2025Article
- Observational
- Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients.NPJ precision oncology · 2025Article
- The initiation of the second-step intradisciplinary tumor board discussion and its impact on treatment decision. Retrospective data analysis of 12 years' experience in a tertiary oncology center.Frontiers in oncology · 2025Article
- Article
- Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy.Journal of managed care & specialty pharmacy · 2024Article
- Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience.Heliyon · 2024Article
- Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.JCO global oncology · 2024Article
- Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies.JCO precision oncology · 2023Article
- Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.Cancer science · 2023Article
- Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.JCO precision oncology · 2023Article
- Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.Hematology reports · 2023Article
- U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario.Frontiers in oncology · 2023Article
- Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information.Experimental hematology & oncology · 2022Review
- Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.Cancers · 2022Article
- Review
- Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With GermlineJCO precision oncology · 2022Review
- Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.The oncologist · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the precision medicine era, molecular testing in advanced cancer is foundational to patient management. Molecular tumor boards (MTBs) can be effective in processing comprehensive genomic profiling (CGP) results and providing expert recommendations. We assessed an MTB and its role in a community setting. This retrospective analysis included patients with MTB recommendations at a community-based oncology practice January 2015 to December 2018; exclusions were death within 60 days of the MTB and/or no metastatic disease. Potentially actionable genomic alterations from CGP (immunohistochemistry, in-situ hybridization, next-generation sequencing) were reviewed bi-weekly by MTB practice experts, pathologists, genetic counselors, and other support staff, and clinical care recommendations were provided. Subsequent chart reviews determined implementation rates of recommendations. In 613 patients, the most common cancers were lung (23%), breast (19%), and colorectal (17%); others included ovarian, endometrial, bladder, and melanoma. Patients received 837 actionable recommendations: standard therapy (37%), clinical trial (31%), germline testing and genetic counseling (17%), off-label therapy (10%), subspecialty multidisciplinary tumor board review (2%), and advice for classifying tumor of unknown origin (2%). Of these recommendations, 36% to 78% were followed by the treating physician. For clinical trial recommendations (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.